Merck Stock History and Valuation

Direct Answer

Merck & Co., Inc. (NYSE: MRK) has been publicly traded for decades under the current corporate structure that dates to a 1927 reorganization. The stock has split six times since 1947, producing a cumulative adjustment factor of approximately 121.5x. Merck joined the Dow Jones Industrial Average on June 29, 1979, replacing Chrysler, and remains one of the longest-tenured members. The company cut its dividend in 2004 after the voluntary withdrawal of Vioxx, then rebuilt its payout over the following years; as of 2024 Merck has increased its dividend for 14 or more consecutive years. At roughly $99 per share in late 2024, the stock traded at approximately 13 times forward earnings with a dividend yield of approximately 3.1%, reflecting a valuation compressed by near-term Keytruda patent-cliff risk approaching 2028.

Stock listing overview

Merck & Co., Inc. trades on the New York Stock Exchange under the ticker symbol MRK. The company's current corporate structure traces to a 1927 reorganization of the original Merck entity. The SEC CIK for Merck is 0000310158.

Stock split history

Merck has split its stock six times since 1947. The cumulative split factor across all six adjustments is approximately 121.5x, calculated as 3 x 3 x 3 x 1.5 x 1.5 x 2. This means a single share held before the first split in 1947 became approximately 121.5 shares after all six adjustments were applied. Merck has not conducted a stock split since February 1999.

The three early 3-for-1 splits between 1947 and 1985 reflect the dramatic price appreciation Merck achieved as it grew from a regional chemical and pharmaceutical operation into a major global drug developer. The two 3-for-2 splits in 1988 and 1992 came during the period when Merck was widely considered among the best-managed companies in the United States, and the final 2-for-1 in 1999 preceded the large Vioxx revenues that ultimately led to the withdrawal crisis five years later.

Unlike companies such as Visa, which executed a single 4-for-1 split after going public, Merck's split history spans more than five decades and reflects the company's long history as a publicly traded operating company rather than as a post-IPO growth stock.

Dow Jones Industrial Average membership

Merck was added to the Dow Jones Industrial Average on June 29, 1979, replacing Chrysler. The addition made Merck one of the few healthcare or pharmaceutical representatives in the index, which was otherwise dominated by industrial, consumer, and financial companies. Merck has held its Dow seat continuously since 1979, making it one of the longest-tenured members of the current Dow 30 composition.

Because the Dow Jones Industrial Average is price-weighted, a stock's per-share price determines how much influence its moves have on the index level. Merck's share price in the range of approximately $99 as of late 2024 places it in the middle tier of Dow components by weight. Merck's role in the index also serves as the primary healthcare bellwether among the 30 components, so its earnings reports and pipeline news carry outsized market attention during reporting seasons.

Dividend history

Merck has a long history of paying dividends. The quarterly dividend reached $0.77 per share ($3.08 annualized) as of fiscal year 2024, and total dividends paid in FY2024 were approximately $7.7 billion. The dividend yield at roughly $99 per share was approximately 3.1% in late 2024. Merck had increased its dividend for 14 or more consecutive years as of 2024, placing it on a trajectory toward Dividend Aristocrat status, which requires 25 consecutive years of increases.

The Vioxx withdrawal in September 2004 forced Merck to reduce its dividend at a time when litigation exposure and lost Vioxx revenues created genuine uncertainty about forward cash generation. This interruption in the dividend growth streak is why Merck is still building toward Dividend Aristocrat status rather than holding it. The multi-year litigation and settlement process tied up capital and management attention from 2004 through approximately 2010, delaying the rebuild of both earnings momentum and dividend growth capacity.

The current dividend growth trajectory reflects the commercial success of Keytruda (pembrolizumab), Merck's leading cancer immunotherapy, which became the company's primary revenue driver through the early 2020s and generated the cash flows that support the current payout level.

Vioxx withdrawal and stock impact

On September 30, 2004, Merck announced the voluntary worldwide withdrawal of Vioxx (rofecoxib), its widely prescribed COX-2 inhibitor pain medication, after a clinical trial showed an increased risk of heart attack and stroke compared to placebo. The announcement came before market open and sent the stock down approximately 27% on the day, from roughly $45 to roughly $33. At the time, this was one of the largest single-day market-capitalization losses for a pharmaceutical company in U.S. history.

The years between 2004 and 2010 represented a period of significant operational and financial uncertainty for Merck. Vioxx had been generating billions of dollars annually in sales, and its removal simultaneously eliminated that revenue stream, triggered an enormous class of product liability litigation, and raised broader questions about Merck's drug development and safety-monitoring processes. The stock traded in a depressed range for several years while the litigation resolved and the company reoriented its pipeline.

The eventual settlement of Vioxx litigation, which Merck resolved for approximately $4.85 billion in November 2007, removed the largest source of tail-risk uncertainty from the stock. Merck's subsequent recovery was gradual rather than immediate: the company had to demonstrate that its pipeline could replace Vioxx revenues, and the clearest evidence only emerged when Keytruda received accelerated approval in 2014 and became the backbone of Merck's post-Vioxx commercial identity.

Valuation framework

Merck traded at approximately 13 times forward earnings in late 2024, based on a share price of roughly $99 and FY2025 consensus earnings per share of approximately $7.85. This multiple represents a discount to the broader S&P 500 and to the typical pharmaceutical sector average, for reasons directly tied to the Keytruda patent timeline.

Forward P/E and the Keytruda patent cliff

Keytruda (pembrolizumab) is one of the best-selling drugs in the world, and Merck derives a substantial portion of its total revenue from it. Keytruda faces biosimilar competition beginning around 2028 when its primary patents expire, a transition investors refer to as the patent cliff. The forward P/E compresses approaching that date because consensus earnings models apply significant probability-weighted discounts to post-2028 earnings, even if Merck's pipeline delivers partial offset. The approximately 13x multiple in late 2024 captures this uncertainty explicitly.

EV/EBITDA

On an enterprise-value-to-EBITDA basis, Merck traded at approximately 12x in late 2024. This measure is often used alongside or instead of P/E for pharmaceutical companies because it is less affected by variations in non-cash charges such as amortization of acquired intangibles, which can be large after acquisitions. Merck's pipeline investments and recent acquisitions mean EBITDA is not a perfect proxy for free cash flow, but the metric is useful for cross-company comparisons.

PEG ratio and near-term growth

The price/earnings-to-growth ratio (PEG) was below 1.0 on a near-term basis in late 2024, driven by Keytruda's continued double-digit volume growth and contributions from Winrevair (sotatercept) and other pipeline assets. A PEG below 1.0 generally signals that a stock is undervalued relative to its near-term growth rate. The complication is that the PEG calculation changes significantly depending on the time horizon used: a three-year forward PEG looks attractive while a five-year forward PEG incorporating the Keytruda cliff looks less so.

Dividend yield as income support

The approximately 3.1% dividend yield at roughly $99 per share is meaningful relative to the S&P 500's average yield and provides an income floor that partially compensates income-oriented investors for patent-cliff uncertainty. Companies with material patent cliffs often see their dividend yield rise as their stock price underperforms the market in anticipation of the cliff, which creates an income opportunity for investors who believe management can navigate the transition with pipeline assets or acquisitions.

Frequently Asked Questions

More on Merck & Co., Inc.

• Merck & Co., Inc. (MRK) company overview

References

• Merck & Co., Inc. Investor Relations
• SEC EDGAR: Merck & Co., Inc. Form 10-K Filings (CIK 0000310158)